CALL FOR PAPERS

CERTIFICATE

IMPACT FACTOR 2018

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

A Study Of Efficacy And Adverse Effect Profile Of First Anti -Epileptic Drug In Children With Newly Diagnosed Epilepsy

Author: 
Dr. Nusrat Bhat, Dr. Kavita Srivastava and Dr. Sanjay Lalwani
Subject Area: 
Health Sciences
Abstract: 

Introduction: Limited data are available for the effectiveness of the antiepileptic drugs in children in daily clinical practice. The AED chosen for initial therapy should be one that is highly effective for the particular seizure type or syndrome and that is safe and well tolerated. The present prospective study was designed to investigate the interaction among efficacy, tolerability, and overall effectiveness of the first antiepileptic drug in children with newly diagnosed epilepsy. Method: Out of 149 children in which (64 females and 85 males) who received valproate 56 (n = 37.6%), Oxcarbazepine 70(n = 47%), levetir-acetam 8(n = 5.4%), carbamazepine 8 (n= 5.4%), 5(n = 3.4%) received phenobarbitone monotherapy as the first-line treatment, were enrolled in the study. Seizure control and the occurrence of adverse events were assessed at 3 months and 6 months respectively. We demonstrated the outcome of epilepsy in relation to several demographic (age and gender), pharmacological and clinical aspects. Results: Overall 110 (73.8%) were seizure free at 3 months and 130(87.2%) were seizure free at 6 months respectively. Out of which 101(67.78%) patients had focal epilepsy and 17(11.40%) had generalized epilepsy and 31(20.8%) had unclassified epilepsy. The majority of seizure free patients required only moderate daily dose of the antiepileptic drug. Valproate and Carbamazepine (the most commonly prescribed antiepileptic drugs). The reasons for treatment failures were lack of seizure control and intolerable adverse events in some patients. Conclusion: In conclusion, the majority of patients with newly diagnosed Epilepsy become seizure free with the first line anti epileptic drugs (Oxcarbazepine/ carbamazepine) for focal epilepsy and valproate for generalised epilepsy) in our daily clinical practice. Oxcarbazepine and valproate treatment is effective, safe and well tolerable in our children with newly diagnosed epilepsy.

PDF file: 

IJMCE RECOMMENDATION

ONLINE PAYPAL PAYMENT

CURRENT ISSUE

NEWS

CHIEF EDITOR
Rosane Cavalcante Fragoso, Brasil
ASSOCIATE CHIEF EDITOR

   

Jean-Marc SABATIER
Chief Scientific Officer and Head of a Research Group
France

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

EDITORIAL BOARD

Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran